- Home
- HUMAW
HUMAW
Humacyte Inc. Warrant
as 07-26-2024 4:00pm EST
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.
| Founded: | N/A | Country: | United States |
| Employees: | 185 | City: | DURHAM |
| Market Cap: | N/A | IPO Year: | 2020 |
| Target Price: | N/A | AVG Volume (30 days): | N/A |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | N/A | Next Earning Date: | N/A |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Humacyte Inc. Warrant News
HUMAW Breaking Stock News: Dive into HUMAW Ticker-Specific Updates for Smart Investing
GlobeNewswire
11 days ago
Humacyte Board of Directors Strengthened with Addition of John P. Bamforth and Keith Anthony Jones
Business Wire
17 days ago
Pluristyx Announces License Agreement with Humacyte to Develop BioVascular Pancreas using iPSCs
Simply Wall St.
25 days ago
While institutions own 20% of Humacyte, Inc. (NASDAQ:HUMA), individual investors are its largest shareholders with 50% ownership
GlobeNewswire
a month ago
Humacyte Acellular Tissue Engineered Vessel (ATEV™) Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for Patients with Advanced Peripheral Artery Disease (PAD)
GlobeNewswire
a month ago
Humacyte Presents Positive Preclinical Data For Its BioVascular Pancreas (BVP™) Program
GlobeNewswire
a month ago
Centers for Medicare & Medicaid Services (CMS) Issues ICD-10-PCS Codes for Humacyte’s Human Acellular Vessel™ (HAV™)
Business Wire
2 months ago
Net Asset Value(s)
GlobeNewswire
2 months ago
Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval
Compare HUMAW vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HUMAW Humacyte Inc. Warrant - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.